Nymox Pharmaceutical specializes in the research and development of novel drugs and diagnostic products for the aging population. Nymox’s lead drug candidate is NX-1207, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH). NX-1207 is currently in Phase 3 trials in the United States. Nymox has other new drug products in development in the fields of cancer, infectious disease, neurodegenerative diseases, and other areas.
|Bank Name||Nymox Pharmaceutical Corporation|
|Industry||In Vitro & In Vivo Diagnostic Substances|
|Chairman||Dr. Paul Averback|
|CEO||Dr. Paul Averback|